Principal Financial Group Inc. Sells 182,261 Shares of TG Therapeutics, Inc. $TGTX

Principal Financial Group Inc. decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 21.5% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 665,526 shares of the biopharmaceutical company’s stock after selling 182,261 shares during the period. Principal Financial Group Inc.’s holdings in TG Therapeutics were worth $22,109,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Danske Bank A S purchased a new position in shares of TG Therapeutics in the 3rd quarter worth approximately $25,000. Hantz Financial Services Inc. increased its position in shares of TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 560 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 573 shares during the last quarter. Truvestments Capital LLC increased its position in shares of TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in TG Therapeutics during the fourth quarter worth $52,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Down 0.0%

NASDAQ:TGTX opened at $53.95 on Wednesday. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $8.26 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 1.35 and a beta of 1.60. The firm’s 50 day moving average is $48.19 and its 200 day moving average is $37.54. TG Therapeutics, Inc. has a 12 month low of $25.28 and a 12 month high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The firm had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. During the same quarter in the previous year, the company posted $0.03 EPS. TG Therapeutics’s revenue for the quarter was up 69.5% on a year-over-year basis. Sell-side analysts expect that TG Therapeutics, Inc. will post 1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TGTX. HC Wainwright boosted their price objective on TG Therapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Bank of America lifted their target price on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. Finally, Jefferies Financial Group restated a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a research report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.33.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.